0001628280-20-001023.txt : 20200205 0001628280-20-001023.hdr.sgml : 20200205 20200205094458 ACCESSION NUMBER: 0001628280-20-001023 CONFORMED SUBMISSION TYPE: IRANNOTICE PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200205 DATE AS OF CHANGE: 20200205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVO NORDISK A S CENTRAL INDEX KEY: 0000353278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: IRANNOTICE SEC ACT: 1934 Act SEC FILE NUMBER: 333-82318 FILM NUMBER: 20576586 BUSINESS ADDRESS: STREET 1: NOVO ALLE DK 2880 CITY: BAGSVAERD DENMARK STATE: G7 ZIP: 00000 BUSINESS PHONE: 4544448888 MAIL ADDRESS: STREET 1: NOVO ALLE DK 2880 CITY: BAGSVAERD DENMARK STATE: G7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: NOVO NORDISK A/S DATE OF NAME CHANGE: 19900807 FORMER COMPANY: FORMER CONFORMED NAME: NOVO INDUSTRI A S /DENMARK/ DATE OF NAME CHANGE: 19890811 IRANNOTICE 1 irannotice.htm IRANNOTICE Document





U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549


February 5, 2020        

Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act



Dear Sirs,

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novo Nordisk A/S has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission on February 5, 2020.



Sincerely,


/s/ Lars Fruergaard Jørgensen
 
/s/ Karsten Munk Knudsen

Lars Fruergaard Jørgensen
President and Chief Executive Officer
 

Karsten Munk Knudsen
Executive Vice President and
Chief Financial Officer